Summary

Report Details

The Biosimilars and Follow-On Biologics Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Regulatory Hurdles Slowing Down Access to Biosimilars
Even in mature areas where regulations for standard generics have been in place for some time, there are still certain challenges, particularly with regard to sophisticated generics. Product categories like respiratory and some long-acting injectables, for instance, still require a large amount of evidence production, which drives up costs and restricts the availability of generics in these markets. This is frequently accompanied by intellectual property (IP) disputes and legal actions, wherein originators are granted prolonged protection periods beyond the initial time intended for the submitted innovation, delaying Generics access.

In a similar vein, clinical trial expenses continue to be exorbitant despite the fact that the regulatory pathways for biosimilars have been well delineated. Even if it is predicted that improvements in regulatory science and characterisation abilities would lessen the necessity for such restrictions, this places researchers and producers at a high degree of risk.

Some emerging nations are still having trouble establishing the proper regulatory environment to facilitate quicker product development. While these variables have an impact on the development of generics and biosimilars, they have a stronger influence when players attempt to build a more inventive pipeline. It will be important to further simplify regulatory requirements to speed up market access while ensuring adequate quality and efficacy.

Emerging Economies Continues to Pose Challenges for Building Presence for Generics and Biosimilars Companies
While emerging nations provide a substantial development potential and an essential playing field for greater access to medicines, they also present major structural and competitive market challenges for generics and biosimilars enterprises. While fierce local competition makes it challenging for players to establish a presence in these markets, additional factors like unstable economic conditions, price controls, the push for local manufacturing in some markets, and shifting regulatory requirements across geographies are all affecting players’ ability to successfully focus on these markets. It may also be less enticing for international firms to join in and assist the development of these markets due to currency repercussions in certain of the countries. Past partnerships and acquisitions have had varying degrees of success, which has limited overall growth performance for players in these fields.

In these conditions, local players who are familiar with the dynamics of their own marketplaces may have an even greater potential to grow developing economies. International players will need to concentrate on careful selection of target nations (e.g., markets with legislative requirements that are comparable to other markets, such as the US and EU) and implement a tailored portfolio approach to avoid costly expansion initiatives with little immediate return.

What Questions Should You Ask before Buying a Market Research Report?
• How is the biosimilars and follow-on biologics market evolving?
• What is driving and restraining the biosimilars and follow-on biologics market?
• How will each biosimilars and follow-on biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each biosimilars and follow-on biologics submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading biosimilars and follow-on biologics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the biosimilars and follow-on biologics projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
biosimilars and follow-on biologics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the biosimilars and follow-on biologics market?
• Where is the biosimilars and follow-on biologics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the biosimilars and follow-on biologics market today, and over the next 10 years:
• Our 337-page report provides 127 tables and 154 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the biosimilars and follow-on biologics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Type of Manufacturing
• In-House
• CMOs

Type
• Monoclonal Antibodies
• Fusion Proteins
• Insulin
• Erythropoietin
• Granulocyte-Colony Stimulating Factor
• Interferon
• Growth Hormones
• Fertility Hormones
• Others

Application
• Blood Disorders
• Oncology Diseases
• Chronic & Autoimmune Diseases
• Growth Hormone Deficiencies
• Others

Technology
• RDNA Technology
• MAbs Technology
• Bioassay Technology

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Biosimilars and Follow-on Biologics Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• 3SBio, Inc.
• AMEGA Biotech
• Amgen Inc.
• Apotex, Inc.
• BIOCAD
• Biocon Limited
• Biogen, Inc.
• Celltrion Healthcare Co., Ltd.
• Coherus BioSciences
• Dr. Reddy’s Laboratories Ltd.
• Eli Lilly and Company
• Gedeon Richter PLC
• Intas Pharmaceutical Ltd.
• Mabxience SA
• Viatris Inc. (Mylan NV)
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis Co. Ltd.
• Stada Arzneimittel AG
• Teva Pharmaceutical

Overall world revenue for Biosimilars and Follow-on Biologics Market, 2023 to 2033 in terms of value the market will surpass US$19,668 million in 2022, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biosimilars and Follow-on Biologics Market, 2023 to 2033 report help you?
In summary, our 330+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Biosimilars and Follow-on Biologics Market, 2023 to 2033 Market, with forecasts for Type of Manufacturing, Type, Application, Technology each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 18 key national markets – See forecasts for the Biosimilars and Follow-on Biologics Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 20 of the major companies involved in the Biosimilars and Follow-on Biologics Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Biosimilars and Follow-on Biologics Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

Table of Contents

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Biosimilars and Follow-on Biologics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Incentivizing Providers to Adopt Biosimilars
3.2.1.2 Developed Regions Driving the Worldwide Biosimilars and Follow-on Biologics Market Growth
3.2.1.3 Biologics Patent Expiry Set to Open Fresh Revenue Pockets for Biosimilars Companies Over the Next Decade
3.2.1.4 Pricing Advantage of Biosimilars Comparison to Biologics Anticipated to Fuel Market Growth
3.2.2 Market Restraining Factors
3.2.2.1 High Cost Involvement, Uncertainty and Complexities in Manufacturing
3.2.2.2 Resistance from Biologics Manufacturers to Restrain Market Growth
3.2.2.3 Reluctance of Healthcare Providers to Switch to Biosimilars
3.2.3 Market Opportunities
3.2.3.1 Companies Can Use Information of Original Innovator thus Shorten Development & Approval Processes
3.2.3.2 Diversity in Approach Among the Authorities
3.3 Trends
3.3.1 Regulatory Hurdles Slowing Down Access to Biosimilars
3.3.2 Vulnerability of Global Pharmaceutical Manufacturing Amid COVID-19
3.3.3 Emerging Economies Continues to Pose Challenges for Building Presence for Generics and Biosimilars Companies
3.3.4 Digital Transformations as a Key Enabler to Strengthen Research in Biosimilars Industry
3.4 COVID-19 Impact Analysis
3.5 Porter’s Five Forces Analysis
3.5.1 Supplier Power
3.5.2 Buyer Power
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis
3.6.1 Political Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.2 Economic Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.3 Social Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.4 Technological Factors Impacting Biosimilars and Follow-on Biologics Market

4 Biosimilars and Follow-on Biologics Market Analysis by Type of Manufacturing
4.1 Key Findings
4.2 Type of Manufacturing Segment: Market Attractiveness Index
4.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Type of Manufacturing
4.4 In-House
4.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 CMOs
4.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.5.2 Market Share by Region, 2023 & 2033 (%)

5 Biosimilars and Follow-on Biologics Market Analysis by Type
5.1 Key Findings
5.2 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Type
5.3 Monoclonal Antibodies
5.3.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.3.2 Market Share by Region, 2023 & 2033 (%)
5.4 Fusion Proteins
5.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Insulin
5.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Erythropoietin
5.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Granulocyte-Colony Stimulating Factor
5.7.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 Interferon
5.8.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.8.2 Market Share by Region, 2023 & 2033 (%)
5.9 Growth Hormones
5.9.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.9.2 Market Share by Region, 2023 & 2033 (%)
5.10 Fertility Hormones
5.10.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.10.2 Market Share by Region, 2023 & 2033 (%)
5.11 Others
5.11.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.11.2 Market Share by Region, 2023 & 2033 (%)

6 Biosimilars and Follow-on Biologics Market Analysis by Application
6.1 Key Findings
6.2 Application Segment: Market Attractiveness Index
6.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Application
6.4 Blood Disorders
6.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Oncology Diseases
6.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Chronic & Autoimmune Diseases
6.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.6.2 Market Share by Region, 2023 & 2033 (%)
6.7 Growth Hormone Deficiencies
6.7.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.7.2 Market Share by Region, 2023 & 2033 (%)
6.8 Others
6.8.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.8.2 Market Share by Region, 2023 & 2033 (%)

7 Biosimilars and Follow-on Biologics Market Analysis by Technology
7.1 Key Findings
7.2 Technology Segment: Market Attractiveness Index
7.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Technology
7.4 rDNA Technology
7.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.5 mAbs Technology
7.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
7.5.2 Market Share by Region, 2023 & 2033 (%)
7.6 Bioassay Technology
7.6.1.1 Chromatography
7.6.1.2 Mass Spectrometry
7.6.1.3 NMR (Nuclear Magnetic Resonance)
7.6.1.4 Electrophoresis
7.6.2 Market Forecast by Region, 2023-2033 (US$ Mn)
7.6.3 Market Share by Region, 2023 & 2033 (%)

8 Biosimilars and Follow-on Biologics Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Biosimilars and Follow-on Biologics Market Analysis
9.1 Key Findings
9.2 North America Biosimilars and Follow-on Biologics Market Attractiveness Index
9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
9.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
9.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
9.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
9.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
9.9 U.S.
9.9.1 United States is Just Beginning to Catch Up European Biosimilars Market
9.9.2 Rising Biosimilar Uptake to Fuel U.S. Biosimilars Market Growth
9.9.3 Advancements in Biosimilars Development and Approvals Across the United States to Fuel Market Growth
9.10 Canada
9.10.1 Biosimilar Authorization Activity Across Canadian Region
9.10.2 Initiatives by Health Canada to Boost Canadian Biosimilars and Follow-on Biologics Market Over the Next Decade
9.10.3 Availability of Biosimilars in Oncology Treatment Landscape Driving Regional Growth
9.10.4 Canada Biosimilars and Follow-on Biologics Market Outlook

10 Europe Biosimilars and Follow-on Biologics Market Analysis
10.1 Key Findings
10.2 Growing Prevalence of Lifestyle Diseases Anticipated to Fuel European Biosimilars Market Growth
10.3 Continued Benefits of Biosimilars to Offer Lucrative Growth Prospects in Long Term
10.4 Europe Biosimilars and Follow-on Biologics Market Attractiveness Index
10.5 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
10.6 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
10.7 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
10.8 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
10.9 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
10.10 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
10.11 Germany
10.11.1 Biosimilars Have Been Accepted as an Important Component of Proper Medication Usage in Germany
10.11.2 Germany Intends to Switch to Biologics Pharmacies by August 2022 thus Jeopardising the Long-Term Viability of Biosimilars
10.11.3 Germany Biosimilars and Follow-on Biologics Market Outlook
10.12 UK
10.12.1 NHS Encouraging the Growth of Biosimilar Manufacturing in United Kingdom
10.12.2 Despite Price Reduction, Biosimilar Medications are not Widely Used in Retail Settings
10.12.3 UK Biosimilars and Follow-on Biologics Market Outlook
10.13 France
10.14 Italy
10.14.1 Italian Government Policies Anticipated to Fuel Development of Biosimilars Market Across the Region
10.14.2 Biosimilars to Help Reduce Price of Pharmaceuticals Across the Italian Region
10.15 Spain
10.15.1 Budget Impact Analysis of Biosimilar Products in Spain
10.16 Rest of Europe

11 Asia Pacific Biosimilars and Follow-on Biologics Market Analysis
11.1 Key Findings
11.2 Low Clinical Development Costs Coupled with Regulatory Framework Ease to Fuel Regional Growth
11.3 Indian Pharmaceutical Companies Have an Enormous Scope in the Biosimilars Market
11.4 Asia Pacific Biosimilars and Follow-on Biologics Market Attractiveness Index
11.5 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
11.6 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
11.7 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
11.8 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
11.9 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
11.10 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
11.11 Japan
11.11.1 Biosimilars to Bolster Japanese Healthcare System Growth Over the Next Decade
11.11.2 Japan still has a slow growth in this sector compared to US and EU
11.11.3 Introduction of Biosimilars to Boost Regional Growth
11.11.4 Ageing Japanese Population Demanding the Development of Biosimilars Over the Forecast Period
11.12 China
11.12.1 Significant Surge in Biosimilar Approvals to Drive Market Growth
11.12.2 Technological Advancements to Fuel Chinese Biosimilars Market Growth Over the Forecast Period
11.12.3 Expansion by Major Firms to Boost Chinese Biosimilars Market Growth
11.12.4 Overcrowding of Chinese Market Has Led to the Withdrawal of International Players
11.13 India
11.13.1 India Set to Become Sixth Largest Pharmaceutical Market By End of 2030
11.13.2 Renowned Pharmaceutical Companies Establishing Partnerships with Indian Pharma Companies
11.13.3 India Biosimilars and Follow-on Biologics Market Outlook
11.14 Rest of Asia Pacific

12 Latin America Biosimilars and Follow-on Biologics Market Analysis
12.1 Key Findings
12.2 Latin America Biosimilars and Follow-on Biologics Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
12.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
12.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
12.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
12.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
12.9 Brazil
12.9.1 Brazilian Biosimilars Regulations
12.10 Mexico
12.11 Rest of Latin America

13 MEA Biosimilars and Follow-on Biologics Market Analysis
13.1 Key Findings
13.2 MEA Biosimilars and Follow-on Biologics Market Attractiveness Index
13.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
13.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
13.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
13.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
13.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
13.9 GCC
13.9.1 GCC Gearing Up to Take Big Jump on Biosimilars
13.9.2 Collaborations Among Pharmaceutical Firms Across GCC to Offer Lucrative Growth Prospects for Market Players Over the Forecast Period
13.10 South Africa
13.10.1 South African Evolving Demographic and Epidemiological Profile to Offer Lucrative Growth Prospects
13.10.2 Presence of Major Pharmaceutical Firms to Intensify Competition
13.11 Rest of MEA

14 Company Profiles
14.1 3SBio, Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Product Benchmarking
14.1.4 Strategic Outlook
14.2 AMEGA Biotech
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Product Benchmarking
14.3 Amgen Inc.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2015-2021
14.3.3.2 R&D Expenses, 2015-2021
14.3.3.3 Gross Profit, 2015-2021
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Apotex, Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Product Benchmarking
14.5 BIOCAD
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Product Benchmarking
14.5.4 Strategic Outlook
14.6 Biocon Limited
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2017-2021
14.6.3.2 R&D Expenses, 2017-2021
14.6.3.3 Biosimilars Sales, 2017-2021
14.6.3.4 Business Segment Market Share, 2021
14.6.3.5 Geographic Market Share, 2021
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Biogen, Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Product Benchmarking
14.8 Celltrion Healthcare Co.,Ltd.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.8.4 Strategic Outlook
14.9 Coherus BioSciences
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Product Benchmarking
14.9.4 Strategic Outlook
14.10 Dr. Reddy’s Laboratories Ltd.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Product Benchmarking
14.11 Eli Lilly and Company
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2015-2021
14.11.3.2 R&D Expenses, 2015-2021
14.11.3.3 Gross Profit, 2015-2021
14.11.3.4 Geographic Revenue, 2018-2021
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Gedeon Richter PLC
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Product Benchmarking
14.12.4 Strategic Outlook
14.13 Intas Pharmaceutical Ltd.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.14 Mabxience SA
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Viatris Inc. (Mylan NV)
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2015-2021
14.15.3.2 R&D Expenses, 2015-2021
14.15.3.3 Gross Profit, 2015-2021
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Novartis AG
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2015-2021
14.16.3.2 R&D Expenses, 2015-2021
14.16.3.3 Gross Profit, 2015-2021
14.16.3.4 Net Sales by Business Segment, 2019-2021
14.16.3.5 Net sales to third parties by business franchise in the Sandoz Division, 2020
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 Pfizer Inc.
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.3.1 Net Revenue, 2015-2021
14.17.3.2 R&D Expenses, 2015-2021
14.17.3.3 Gross Profit, 2015-2021
14.17.3.4 Geographic Market Share, 2021
14.17.4 Product Benchmarking
14.17.5 Strategic Outlook
14.18 Samsung Bioepis Co. Ltd.
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Product Benchmarking
14.18.4 Strategic Outlook
14.19 Stada Arzneimittel AG
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2016-2020
14.19.3.2 Gross Profit, 2016-2020
14.19.3.3 Net Sales by Segment, 2019-2020
14.19.4 Product Benchmarking
14.19.5 Strategic Outlook
14.20 Teva Pharmaceutical
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Financial Analysis
14.20.3.1 Net Revenue, 2015-2021
14.20.3.2 R&D Expenses, 2015-2021
14.20.3.3 Gross Profit, 2015-2021
14.20.4 Product Benchmarking

15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players

List of Tables
Table 1 Biosimilars and Follow-on Biologics Market Snapshot, 2023 & 2033 (US$ million, CAGR %)
Table 2 Biosimilars and Follow-on Biologics Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Biosimilars and Follow-on Biologics Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Biosimilars and Follow-on Biologics Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Biosimilars and Follow-on Biologics Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 7 In-House Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 8 CMOs Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 9 Global Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 10 Monoclonal Antibodies Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 11 Fusion Proteins Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 12 Insulin Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 13 Erythropoietin Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 14 Granulocyte-Colony Stimulating Factor Companies Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 15 Interferon Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 16 Growth Hormones Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 17 Fertility Hormones Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 18 Others Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 19 Global Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 20 Blood Disorders Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 21 Oncology Diseases Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 22 Chronic & Autoimmune Diseases Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 23 Growth Hormone Deficiencies Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 24 Others Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 25 Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 26 rDNA Technology Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 27 Mab Technology Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 28 Bioassay Technology Segment Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 29 Biosimilars and Follow-on Biologics Market Forecast by Region, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 30 North America Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 31 North America Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 32 North America Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 33 North America Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 34 North America Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 35 FDA Approved Biosimilars as of September 2022
Table 36 U.S. Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 37 Canada Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 38 Europe Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 39 Europe Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 40 Europe Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 41 Europe Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 42 Europe Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 43 Germany Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 44 UK Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 45 France Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 46 Italy Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 47 Spain Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 48 Rest of Europe Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 49 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 50 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 51 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 52 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 53 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 54 Japan Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 55 China Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 56 India Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 57 Rest of Asia Pacific Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 58 Latin America Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 59 Latin America Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 60 Latin America Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 61 Latin America Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 62 Latin America Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 63 Brazil Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 64 Mexico Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 65 Rest of Latin America Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 66 MEA Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 67 MEA Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 68 MEA Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 69 MEA Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 70 MEA Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 71 GCC Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 72 South Africa Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 73 Rest of MEA Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ mn, AGR%, CAGR%)
Table 74 3SBio, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 3SBio, Inc.: Product Benchmarking
Table 76 3SBio, Inc.: Strategic Outlook
Table 77 AMEGA Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 AMEGA Biotech: Product Benchmarking
Table 79 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 Amgen Inc.: Product Benchmarking
Table 81 Amgen Inc.: Strategic Outlook
Table 82 Apotex, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Apotex, Inc.: Product Benchmarking
Table 84 BIOCAD: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 BIOCAD: Product Benchmarking
Table 86 BIOCAD: Strategic Outlook
Table 87 Biocon Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Biocon Limited: Product Benchmarking
Table 89 Biocon Limited: Strategic Outlook
Table 90 Biogen, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Biogen, Inc.: Product Benchmarking
Table 92 Celltrion Healthcare Co.,Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Celltrion Healthcare Co.,Ltd.: Product Benchmarking
Table 94 Celltrion Healthcare Co.,Ltd.: Strategic Outlook
Table 95 Coherus BioSciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Coherus BioSciences: Product Benchmarking
Table 97 Coherus BioSciences: Strategic Outlook
Table 98 Dr. Reddy’s Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Dr. Reddy’s Laboratories Ltd.: Product Benchmarking
Table 100 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Eli Lilly and Company: Product Benchmarking
Table 102 Eli Lilly and Company: Strategic Outlook
Table 103 Gedeon Richter PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Gedeon Richter PLC: Product Benchmarking
Table 105 Gedeon Richter PLC: Strategic Outlook
Table 106 Intas Pharmaceutical Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Intas Pharmaceutical Ltd.: Product Benchmarking
Table 108 Mabxience SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Mabxience SA: Product Benchmarking
Table 110 Mabxience SA: Strategic Outlook
Table 111 Viatris Inc. (Mylan NV): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Viatris Inc. (Mylan NV): Product Benchmarking
Table 113 Viatris Inc. (Mylan NV): Strategic Outlook
Table 114 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Novartis AG: Product Benchmarking
Table 116 Novartis AG: Strategic Outlook
Table 117 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Pfizer Inc.: Product Benchmarking
Table 119 Pfizer Inc.: Strategic Outlook
Table 120 Samsung Bioepis Co. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Samsung Bioepis Co. Ltd.: Product Benchmarking
Table 122 Samsung Bioepis Co. Ltd.: Strategic Outlook
Table 123 Stada Arzneimittel AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Stada Arzneimittel AG: Product Benchmarking
Table 125 Stada Arzneimittel AG: Strategic Outlook
Table 126 Teva Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 127 Teva Pharmaceutical: Strategic Outlook
 
List of Figures
Figure 1 Biosimilars and Follow-on Biologics Market Segmentation
Figure 2 Biosimilars and Follow-on Biologics Market by Type of Manufacturing: Market Attractiveness Index
Figure 3 Biosimilars and Follow-on Biologics Market by Application: Market Attractiveness Index
Figure 4 Biosimilars and Follow-on Biologics Market by Technology: Market Attractiveness Index
Figure 5 Biosimilars and Follow-on Biologics Market Attractiveness Index by Region
Figure 6 Biosimilars and Follow-on Biologics Market: Market Dynamics
Figure 7 Biologics Patent Expiry, 2020-2030
Figure 8 Biosimilars and Follow-on Biologics Market by Region, 2023-2033 (US$ Mn, AGR %): “V” Shaped Recovery
Figure 9 Biosimilars and Follow-on Biologics Market by Region, 2023-2033 (US$ Mn, AGR %): “U” Shaped Recovery
Figure 10 Biosimilars and Follow-on Biologics Market by Region, 2023-2033 (US$ Mn, AGR %): “W” Shaped Recovery
Figure 11 Biosimilars and Follow-on Biologics Market by Region, 2023-2033 (US$ Mn, AGR %): “L” Shaped Recovery
Figure 12 Biosimilars and Follow-on Biologics Market: Porter’s Five Forces Analysis
Figure 13 Biosimilars and Follow-on Biologics Market: PEST Analysis
Figure 14 Biosimilars and Follow-on Biologics Market Attractiveness Index by Type of Manufacturing
Figure 15 Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ million)
Figure 16 Biosimilars and Follow-on Biologics Market Share Forecast by Type of Manufacturing, 2023, 2028, 2033 (%)
Figure 17 In-House Market Forecast by Region, 2023-2033 (US$ million)
Figure 18 In-House Market Share Forecast by Region, 2023 & 2033 (%)
Figure 19 CMOs Market Forecast by Region, 2023-2033 (US$ million)
Figure 20 CMOs Market Share Forecast by Region, 2023 & 2033 (%)
Figure 21 Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ million)
Figure 22 Biosimilars and Follow-on Biologics Market Share Forecast by Type, 2023, 2028, 2033 (%)
Figure 23 Monoclonal Antibodies Market Forecast by Region, 2023-2033 (US$ million)
Figure 24 Monoclonal Antibodies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 25 Fusion Proteins Market Forecast by Region, 2023-2033 (US$ million)
Figure 26 Fusion Proteins Market Share Forecast by Region, 2023 & 2033 (%)
Figure 27 Insulin Market Forecast by Region, 2023-2033 (US$ million)
Figure 28 Insulin Market Share Forecast by Region, 2023 & 2033 (%)
Figure 29 Erythropoietin Market Forecast by Region, 2023-2033 (US$ million)
Figure 30 Erythropoietin Market Share Forecast by Region, 2023 & 2033 (%)
Figure 31 Granulocyte-Colony Stimulating Factor Market Forecast by Region, 2023-2033 (US$ million)
Figure 32 Granulocyte-Colony Stimulating Factor Market Share Forecast by Region, 2023 & 2033 (%)
Figure 33 Interferon Market Forecast by Region, 2023-2033 (US$ million)
Figure 34 Interferon Market Share Forecast by Region, 2023 & 2033 (%)
Figure 35 Growth Hormones Market Forecast by Region, 2023-2033 (US$ million)
Figure 36 Growth Hormones Market Share Forecast by Region, 2023 & 2033 (%)
Figure 37 Fertility Hormones Market Forecast by Region, 2023-2033 (US$ million)
Figure 38 Fertility Hormones Market Share Forecast by Region, 2023 & 2033 (%)
Figure 39 Others Market Forecast by Region, 2023-2033 (US$ million)
Figure 40 Others Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Biosimilars and Follow-on Biologics Market Attractiveness Index by Application
Figure 42 Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ million)
Figure 43 Biosimilars and Follow-on Biologics Market Share Forecast by Application, 2023, 2028, 2033 (%)
Figure 44 Blood Disorders Market Forecast by Region, 2023-2033 (US$ million)
Figure 45 Blood Disorders Market Share Forecast by Region, 2023 & 2033 (%)
Figure 46 Oncology Diseases Market Forecast by Region, 2023-2033 (US$ million)
Figure 47 Oncology Diseases Market Share Forecast by Region, 2023 & 2033 (%)
Figure 48 Chronic & Autoimmune Diseases Market Forecast by Region, 2023-2033 (US$ million)
Figure 49 Chronic & Autoimmune Diseases Market Share Forecast by Region, 2023 & 2033 (%)
Figure 50 Growth Hormone Deficiencies Market Forecast by Region, 2023-2033 (US$ million)
Figure 51 Growth Hormone Deficiencies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 52 Others Market Forecast by Region, 2023-2033 (US$ million)
Figure 53 Others Market Share Forecast by Region, 2023 & 2033 (%)
Figure 54 Biosimilars and Follow-on Biologics Market Attractiveness Index by Technology
Figure 55 Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ million)
Figure 56 Biosimilars and Follow-on Biologics Market Share Forecast by Technology, 2023, 2028, 2033 (%)
Figure 57 rDNA Technology Market Forecast by Region, 2023-2033 (US$ million)
Figure 58 rDNA Technology Market Share Forecast by Region, 2023 & 2033 (%)
Figure 59 mAbs Technology Market Forecast by Region, 2023-2033 (US$ million)
Figure 60 mAbs Technology Market Share Forecast by Region, 2023 & 2033 (%)
Figure 61 Bioassay Technology Market Forecast by Region, 2023-2033 (US$ million)
Figure 62 Bioassay Technology Market Share Forecast by Region, 2023 & 2033 (%)
Figure 63 Biosimilars and Follow-on Biologics Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR%)
Figure 64 Biosimilars and Follow-on Biologics Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 65 Biosimilars and Follow-on Biologics Market by Region, 2023-2033 (US$ Mn)
Figure 66 North America Biosimilars and Follow-on Biologics Market Attractiveness Index
Figure 67 North America Biosimilars and Follow-on Biologics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 68 North America Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ million)
Figure 69 North America Biosimilars and Follow-on Biologics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 70 North America Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ million)
Figure 71 North America Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ million)
Figure 72 North America Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ million)
Figure 73 North America Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ million)
Figure 74 U.S. Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 75 Canada Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 76 Europe Biosimilars and Follow-on Biologics Market Attractiveness Index
Figure 77 Europe Biosimilars and Follow-on Biologics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 78 Europe Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ million)
Figure 79 Europe Biosimilars and Follow-on Biologics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 80 Europe Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ million)
Figure 81 Europe Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ million)
Figure 82 Europe Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ million)
Figure 83 Europe Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ million)
Figure 84 Germany Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 85 UK Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 86 France Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 87 Italy Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 88 Spain Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 89 Rest of Europe Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 90 Asia Pacific Biosimilars and Follow-on Biologics Market Attractiveness Index
Figure 91 Asia Pacific Biosimilars and Follow-on Biologics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 92 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ million)
Figure 93 Asia Pacific Biosimilars and Follow-on Biologics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 94 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ million)
Figure 95 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ million)
Figure 96 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ million)
Figure 97 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ million)
Figure 98 Japan Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 99 Biosimilar Approvals in China vs. Japan & South Korea, 2015-2020
Figure 100 China Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 101 India Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 102 Rest of Asia Pacific Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 103 Latin America Biosimilars and Follow-on Biologics Market Attractiveness Index
Figure 104 Latin America Biosimilars and Follow-on Biologics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 105 Latin America Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ million)
Figure 106 Latin America Biosimilars and Follow-on Biologics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 107 Latin America Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ million)
Figure 108 Latin America Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ million)
Figure 109 Latin America Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ million)
Figure 110 Latin America Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ million)
Figure 111 Brazil Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 112 Mexico Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 113 Rest of Latin America Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 114 MEA Biosimilars and Follow-on Biologics Market Attractiveness Index
Figure 115 MEA Biosimilars and Follow-on Biologics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 116 MEA Biosimilars and Follow-on Biologics Market Forecast by Country, 2023-2033 (US$ million)
Figure 117 MEA Biosimilars and Follow-on Biologics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 118 MEA Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2023-2033 (US$ million)
Figure 119 MEA Biosimilars and Follow-on Biologics Market Forecast by Type, 2023-2033 (US$ million)
Figure 120 MEA Biosimilars and Follow-on Biologics Market Forecast by Application, 2023-2033 (US$ million)
Figure 121 MEA Biosimilars and Follow-on Biologics Market Forecast by Technology, 2023-2033 (US$ million)
Figure 122 GCC Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 123 South Africa Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 124 Rest of MEA Biosimilars and Follow-on Biologics Market Forecast, 2023-2033 (US$ million)
Figure 125 Amgen Inc.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 126 Amgen Inc.: R&D Expenses, 2015-2021 (US$ million, AGR%)
Figure 127 Amgen Inc.: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 128 Biocon Limited: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 129 Biocon Limited: R&D Expenses, 2017-2021 (US$ million, AGR%)
Figure 130 Biocon Limited: Biosimilars Sales, 2017-2021 (US$ million, AGR%)
Figure 131 Biocon Limited: Business Segment Market Share, 2021 (%)
Figure 132 Biocon Limited: Geographic Market Share, 2021 (%)
Figure 133 Eli Lilly and Company: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 134 Eli Lilly and Company: R&D Expenses, 2015-2021 (US$ million, AGR%)
Figure 135 Eli Lilly and Company: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 136 Eli Lilly and Company: Geographic Revenue, 2018-2021 (US$ million)
Figure 137 Viatris Inc. (Mylan NV): Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 138 Viatris Inc. (Mylan NV): R&D Expenses, 2015-2021 (US$ million, AGR%)
Figure 139 Viatris Inc. (Mylan NV): Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 140 Novartis AG: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 141 Novartis AG: R&D Expenses, 2015-2021 (US$ million, AGR%)
Figure 142 Novartis AG: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 143 Novartis AG: Net Sales by Business Segment, 2019-2021 (US$ million)
Figure 144 Novartis AG: Net sales to third parties by business franchise in the Sandoz Division, 2020 (%)
Figure 145 Pfizer Inc.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 146 Pfizer Inc.: R&D Expenses, 2015-2021 (US$ million, AGR%)
Figure 147 Pfizer Inc.: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 148 Pfizer Inc.: Geographic Revenue Share, 2021 (%)
Figure 149 Stada Arzneimittel AG: Net Revenue, 2016-2020 (US$ million, AGR%)
Figure 150 Stada Arzneimittel AG: Gross Profit, 2016-2020 (US$ million, AGR%)
Figure 151 Stada Arzneimittel AG: Net Income, 2021 (%)
Figure 152 Teva Pharmaceutical: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 153 Teva Pharmaceutical: R&D Expenses, 2015-2021 (US$ million, AGR%)
Figure 154 Teva Pharmaceutical: Gross Profit, 2015-2021 (US$ million, AGR%)